#USA #Raleigh #Endpoint Clinical #Elosity #R3 Release

Endpoint Clinical Unveils Elosity R3: Transforming Clinical Trials

On April 13, 2026, Endpoint Clinical announced the significant launch of the Elosity R3 platform, a comprehensive update aimed at advancing the capabilities of its Randomization and Trial Supply Management (RTSM) system. This new version is specifically designed to better equip sponsors and Clinical Research Organizations (CROs) in dealing with the growing complexities of clinical trials globally.

Expanding Capabilities for Clinical Trials

The Elosity R3 platform introduces an array of innovative features that focus on improving clinical supply operations and study execution. These enhancements include central pharmacy management to streamline drug distribution, flexible sourcing strategies that adapt to varying trial needs, and the ability to manage patient rollover across multiple studies. The update also optimizes supply management at the portfolio level and enhances the tools available for study configuration, regulatory audit readiness, and global access management.

Jeff Rubesin, the Vice President of Product Strategy at Endpoint Clinical, emphasized the significance of the new release. He stated, "Elosity R3 represents a meaningful step forward in how RTSM platforms support modern clinical trials. We built Elosity to connect trial execution, clinical supply operations, and data insight within a single platform. With R3, sponsors and CROs gain faster operational visibility and stronger governance."

AI Integration for Enhanced Insights

One of the standout features of Elosity R3 is the integration of eloAI, the platform's built-in artificial intelligence system. This intelligent assistant enables clinical teams to engage with RTSM and supply chain data through natural language queries. The eloAI functionality delivers immediate insights, visual data representations, and operational analytics right within the Elosity interface. This allows teams to swiftly transition from inquiries to actionable answers while maintaining critical factors such as study blinding and compliance with regulatory standards.

Streamlined Connectivity Across Platforms

Elosity R3 is built upon Endpoint Clinical's cloud-first architecture that emphasizes seamless integration with both clinical and enterprise systems. This structure aims to provide comprehensive visibility throughout the lifecycle of clinical trials, from initiation to completion. As trial complexities increase, the ability to access data and manage supplies seamlessly will be crucial for successful trial outcomes.

Availability and Future of Elosity

The Elosity R3 update is now available for sponsors and CROs around the globe, promising enhanced operational control and clarity during trials. By empowering clients with proactive solutions to common challenges encountered in clinical trials, Endpoint Clinical reaffirms its commitment to supporting the healthcare sector through innovative technology.

For detailed information regarding Endpoint Clinical's RTSM solution and to explore Elosity, visit Endpoint Clinical.

About Endpoint Clinical

Endpoint Clinical is known for its reliable and adaptive solutions within clinical trial technology. With extensive experience in the field, the company offers a profound comprehension of the obstacles that sponsors and CROs face. Their tech-driven approach ensures that risks are managed effectively, allowing stakeholders to focus on executing successful clinical trials. By combining innovative technology with personalized service, Endpoint Clinical remains a trusted partner in advancing the healthcare landscape.